Septerna (NASDAQ:SEPN) Insider Samira Shaikhly Sells 6,250 Shares

Septerna, Inc. (NASDAQ:SEPN) insider Samira Shaikhly sold 6,250 shares of the stock in a transaction on Friday, June 12th. The stock was sold at an average price of $35.08, for a total value of $219,250.00. Following the completion of the sale, the insider owned 793 shares of the company’s stock, valued at $27,818.44. The trade was a 88.74% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through the SEC website.

Samira Shaikhly also recently made the following trade(s):

• On Monday, June 1st, Samira Shaikhly sold 5,935 shares of Septerna stock. The stock was sold at an average price of $28.93, for a total value of $171,699.55.
• On Tuesday, May 26th, Samira Shaikhly sold 11,798 shares of Septerna stock. The shares were sold at an average price of $30.06, for a total transaction of $354,647.88.

Septerna Stock Performance

Shares of SEPN traded down $0.86 during midday trading on Tuesday, hitting $35.17. 284,028 shares of the company traded hands, compared to its average volume of 299,736. The firm has a 50 day moving average of $27.39 and a 200-day moving average of $26.88. Septerna, Inc. has a 52 week low of $9.85 and a 52 week high of $37.01. The stock has a market cap of $1.59 billion, a price-to-earnings ratio of -43.42 and a beta of 2.39.

Septerna (NASDAQ:SEPN) last released its quarterly earnings data on Tuesday, May 12th. The company reported ($0.19) EPS for the quarter, beating the consensus estimate of ($0.42) by $0.23. Septerna had a negative net margin of 49.88% and a negative return on equity of 12.72%. The business had revenue of $26.52 million during the quarter, compared to the consensus estimate of $16.98 million. Sell-side analysts predict that Septerna, Inc. will post -1.57 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several research firms have commented on SEPN. Cantor Fitzgerald reissued an “overweight” rating and set a $60.00 price objective on shares of Septerna in a report on Tuesday, March 10th. Wells Fargo & Company increased their price target on shares of Septerna from $28.00 to $48.00 and gave the company an “overweight” rating in a report on Tuesday, March 3rd. JPMorgan Chase & Co. increased their price target on shares of Septerna from $34.00 to $38.00 and gave the company an “overweight” rating in a report on Tuesday, March 24th. Raymond James Financial raised their price objective on Septerna from $47.00 to $53.00 and gave the company a “strong-buy” rating in a research note on Monday, June 8th. Finally, Wall Street Zen cut Septerna from a “buy” rating to a “hold” rating in a report on Saturday, March 14th. Two investment analysts have rated the stock with a Strong Buy rating, seven have given a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $45.78.

Institutional Trading of Septerna

Several institutional investors and hedge funds have recently modified their holdings of the stock. Deutsche Bank AG raised its stake in shares of Septerna by 5.3% during the fourth quarter. Deutsche Bank AG now owns 14,879 shares of the company’s stock valued at $415,000 after acquiring an additional 744 shares in the last quarter. Global Retirement Partners LLC bought a new position in Septerna in the fourth quarter worth approximately $35,000. JPMorgan Chase & Co. raised its stake in Septerna by 15.0% in the second quarter. JPMorgan Chase & Co. now owns 10,101 shares of the company’s stock worth $107,000 after buying an additional 1,315 shares in the last quarter. PharVision Advisers LLC raised its stake in Septerna by 17.5% in the third quarter. PharVision Advisers LLC now owns 11,932 shares of the company’s stock worth $224,000 after buying an additional 1,780 shares in the last quarter. Finally, Nuveen LLC raised its stake in Septerna by 7.7% in the fourth quarter. Nuveen LLC now owns 25,798 shares of the company’s stock worth $719,000 after buying an additional 1,837 shares in the last quarter.

Septerna Company Profile

We are a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) oral small molecule drug discovery powered by our proprietary Native Complex Platform™. Our industrial-scale platform aims to unlock the full potential of GPCR therapies and has led to the discovery and development of our deep pipeline of product candidates focused initially on treating patients in three therapeutic areas: endocrinology, immunology and inflammation, and metabolic diseases. GPCRs are the largest and most diverse family of cell membrane receptors and regulate physiological processes in nearly every organ system of the human body.